59 results about "Eicosatetraenoic acid" patented technology

The present invention relates to fatty acid desaturases and elongases able to catalyze the conversion of linoleic acid (LA) to γ-linolenic acid (GLA); α-linoleic acid (ALA) to stearidonic acid (STA); GLA to dihomo-γ-linoleic acid (DGLA); STA to eicosatetraenoic acid (ETA); DGLA to ETA; eicosapentaenoic acid (EPA) to docosapentaenoic acid (DPA); and arachidonic acid (ARA) to EPA. Nucleic acid sequences encoding codon-optimized desaturases and elongases, nucleic acid sequences which hybridize thereto, DNA constructs comprising the codon-optimized desaturase or elongases, and recombinant host microorganisms expressing increased levels of desaturase or elongase are described.

The present invention relates to methods for the production of ω-3 and / or ω-6 fatty acids in oleaginous yeast. Thus, desaturases and elongases able to catalyze the conversion of linoleic acid (LA) to γ-linolenic acid (GLA); α-linoleic acid (ALA) to stearidonic acid (STA); GLA to dihomo-γ-linoleic acid (DGLA); STA to eicosatetraenoic acid (ETA); DGLA to arachidonic acid (ARA); ETA to eicosapentaenoic acid (EPA); DGLA to ETA; EPA to docosapentaenoic acid (DPA); and ARA to EPA have been introduced into the genome of Yarrowia for synthesis of ARA and EPA.

The present invention relates to methods for the production of ω-3 and / or ω-6 fatty acids in oleaginous yeast. Thus, desaturases and elongases able to catalyze the conversion of linoleic acid (LA) to γ-linolenic acid (GLA); α-linoleic acid (ALA) to stearidonic acid (STA); GLA to dihomo-γ-linoleic acid (DGLA); STA to eicosatetraenoic acid (ETA); DGLA to arachidonic acid (ARA); ETA to eicosapentaenoic acid (EPA); DGLA to ETA; EPA to docosapentaenoic acid (DPA); and ARA to EPA have been introduced into the genome of Yarrowia for synthesis of ARA and EPA.

The production and use, and in particular, the extraction, separation, synthesis and recovery of polar lipid-rich fractions containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA(n-3) or DPA(n-6)), arachidonic acid (ARA), and eicosatetraneonoic acid (C20:4n-3) from microorganisms, genetically modified seeds and marine organisms (including fish and squid) and their use in human food applications, animal feed, pharmaceutical applications and cosmetic applications.

The present invention relates to mutant Δ8 desaturase genes, which have the ability to convert eicosadienoic acid [20:2 ω-6, EDA] to dihomo-γ-linolenic acid [20:3, DGLA] and / or eicosatrienoic acid [20:3 ω-3, ETrA] to eicosatetraenoic acid [20:3 ω-3, ETA]. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding Δ8 desaturase along with methods of making long-chain polyunsaturated fatty acids (PUFAs) using these mutant Δ8 desaturases in plants and oleaginous yeast are disclosed.

The present invention relates to mutant Δ5 desaturases, which have the ability to convert dihomo-γ-linolenic acid [DGLA; 20:3 ω-6] to arachidonic acid [ARA; 20:4 ω-6] and / or eicosatetraenoic acid [ETA; 20:4 ω-3] to eicosapentaenoic acid [EPA; 20:5 ω-3] and which possess at least one mutation within the HPGG motif of the cytochrome b5-like domain. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding Δ5 desaturases, along with a method of making long chain polyunsaturated fatty acids [“PUFAs”] using these mutant Δ5 desaturases in oleaginous yeast, are disclosed.

The invention relates to a nutritional composition comprising (a) at least 18 en% of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt% of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least an Omega-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving dailyactivity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.

The invention discloses an infant formula added with combined prebiotics and a preparation method thereof, and relates to the technical field of dairy processing; the infant formula is prepared from, by weight percent, 92-98% of base powder, 0-0.5% of concentrated whey protein, 0.1-0.35% of casein phosphopeptides, 0.22-1.1% of docosahexaenoic acid, 0.25-1.0% of eicosatetraenoic acid, 0.3-0.5% of composite vitamin, 0.15-0.2% of mineral substance, 0.25-0.3% of calcium carbonate, 0.1-0.2% of tricalcium phosphate, 0.02-0.05% of nucleotide, 0.3-0.5% of choline chloride, and 0.5-6.4% of combined prebiotics. The combined prebiotics contained the milk powder can promote the growth and breeding of bifidobacterium or lactobacillus and other probiotics in the intestinal tract, and improve microenvironment of intestinal tract, and is good for maintaining normal intestinal tract function, and has the similar effect of oligosaccharide of breast milk.

The present invention relates to an infant formula milk powder and a preparation method thereof. Hydrolyzed whey protein powder, nucleotides and lactoferrin are added in the infant formula milk powder based on the original infant milk powder, and the infant formula milk powder is prepared by using a dry mixing method. The beneficial effects of the infant formula milk powder are that the hydrolyzed whey protein powder, nucleotides and lactoferrin are added into the infant milk powder to enable the infant milk powder to be closer to breast milk and to enhance the resistance of infants. Docosahexaenoic acids and eicosatetraenoic acids in the milk powder are essential for infant mental and visual developments. The drying process avoids the heat of nutritional enhancer, prevents the destruction of heat-sensitive components, and thus ensures the nutrition and function of the product and enables the milk powder to be more conducive to digestion, absorption, and organism protection of infants.

The invention relates to a nutritional composition comprising (a) at least 18 en% of proteinaceous matter; (b) at least 12 wt% of leucine, based on total proteinaceous matter: (C) a lipid fraction comprising at least an omega-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid; and (d) an immune modulator; for improving the immune function in a mammal, preferably a human.

The invention discloses a method for preparing a food supplement with a function of improving eyesights of infants and children. The food supplement comprises the following components: vitamin A, vitamin C, vitamin B2, vitamin E, docosahexaenoic acid (DHA), eicosatetraenoic acid (AA), taurine, calcium lactate, zinc gluconate and calcium lactate as well as carrot meal, chrysanthemum, medlar, walnut kernel and spina date seed which are edible and pharmaceutical, wherein the components are the traditional good health care food raw materials or foods and have no toxic or side effect.

The invention relates to a health product, which is characterized in that: the health product comprises timnodonic acid, docosahexaenoic acid, hexadecenoic acid, octadecenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid and docosapentaenoic acid, wherein the mass summation of the timnodonic acid and the docosahexaenoic acid accounts for 35 to 40 percent of the total mass, and the mass summation of the hexadecenoic acid, the octadecenoic acid, the octadecadienoic acid, the octadecatrienoic acid, the eicosatetraenoic acid and the docosapentaenoic acid accounts for 60 to 75 percent of the total mass. The contents of fish oil extracts EPA and DHA prepared by the method are between 35 and 40 percent; and the deep sea fish oil prepared from the extracts taken as main raw materials has the advantages of having an obvious lipid-reducing effect, diversifying active ingredients, and achieving the effects of inhibiting platelet aggregation, lowering neutral lipid in blood, lowering cholesterol of low density lipoprotein and low density lipoprotein, increasing high density cholesterol, lowering blood viscosity, lowering cholesterol, preventing heart cerebrovascular diseases, reducing arterial pressure, alleviating gout and rheumatoid arthritis, improving the development of the brain and eyes and the like, so that the health product is the best choice of middle and old-aged people.

The present invention relates to mutant delta-8 desaturase genes, which have the ability to convert eicosadienoic acid [20:2 omega-6, EDA] to dihomo-γ-linolenic acid [20:3, DGLA] and / or eicosatrienoic acid [20:3 omega-3, ETrA] to eicosatetraenoic acid [20:3 omega-3, ETA]. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding delta-8 desaturase along with methods of making long-chain polyunsaturated fatty acids (PUFAs) using these mutant delta-8 desaturases in plants and oleaginous yeast are disclosed.

The invention discloses an algal soft capsule containing arachidonic acid. The soft capsule mainly contains following active ingredients: algal oil (containing DHA (docosahexenoic acid) and free from EPA), arachidonic acid (AA (eicosatetraenoic acid)), lecithin (PC (phosphatidylcholine)) and vitamin E, as well as auxiliary materials such as water, glycerol and edible animal gelatin. According to the algal oil soft capsule disclosed by the invention, multiple nutrient substances, namely, DHA, AA and PC, important for brain growth and development are effectively combined, and the ingredients are further coordinated to play the roles of improving memory, eliminating brain fatigue, and enhancing concentration and attention. Moreover, the algal oil soft capsule is safe and reliable, and free from EPA ingredient which can promote premature of children.

The invention provides structure grease containing eicosatetraenoic acid. In the structure grease, eicosatetraenoic acid at the Sn-1,3 site accounts for over 40% (in terms of weight) of total fatty acid, and palmitic acid at the Sn-2 site accounts for over 50% (in terms of weight) of total palmitic acid. The invention also provides a preparation method of the structure grease. The structure grease disclosed by the invention contains eicosatetraenoic acid, eicosatetraenoic acid at the Sn-1,3 site and palmitic acid at the Sn-2 site are easily digested and absorbed by a human body, eicosatetraenoic acid is supplemented when palmitic acid at the Sn-2 site is provided, and the humanization direction of fat is met. Therefore, the structure grease can be applied to infant formula food, and other foods or health products requiring eicosatetraenoic acid.

The present invention provides a formula of a cereal complementary food nutritious meal for infants having effects of strengthening spleen and tonifying stomach, promoting digestion and benefiting qi, moistening lungs and clearing heat, and supplementing needed minerals and vitamins for the infants in a growth period and a processing method thereof. The formula is as follows: rice is subjected to a saccharifying to enable starch to be hydrolyzed into dextrin, at the same time, lysozyme is added, endothelium corneum gigeriae galli is subjected to a salt stir-frying and a vinegar stir-frying, and then soybean flour, skimmed milk powder, crystal sugar, glucose, Chinese yam powder, lotus seed powder, celery powder, soybean protein isolate, whey proteins, fruit and vegetable powder, maltodextrin, compound minerals (calcium carbonate, zinc oxide and ferric pyrophosphate), multivitamins (vitamin A, vitamin D, vitamin B1, vitamin B2 and vitamin C) and other nutrients (DHA (docosahexaenoic acid), ARA (arachidonic acid), fructo-oligosaccharides, galactooligosaccharides, stachyose, probiotics and hydrolyzed whey proteins) are used as main raw materials. The processing method is combined with a steam roller drying technology, and the cereal complementary food nutritious meal for the infants is prepared by mixing.

The invention relates to the field of formula milk powder, and discloses immunomodulatory milk powder and a preparation method thereof. The immunomodulatory milk powder comprises the components: raw milk, desalted whey powder, concentrated whey protein powder, isomalto-oligosacharide, fructo-oligosaccharide, galacto-oligosaccharide, oat beta-glucan, goat colostrum powder, N-acetylneuraminic acid,stachyose, wheat oligopeptide, corn oligopeptide, lactase, DHA algae oil powder, eicosapentaenoic acid, composite vitamins, folic acid, taurine, composite minerals, calcium carbonate and composite probiotics. In the preparation process of the milk powder, components which are not prone to loss at high temperature are added into bovine colostrum through a wet method in the earlier stage, then spraydrying is conducted, dried powdery substances are mixed with remaining components, and loss of nutrient substances in the preparation process of the milk powder is reduced. Meanwhile, a formula of mixing raw milk and goat colostrum is adopted, so that the immunity of infants is improved, and the infants are helped to establish a mature immune system.

The invention provides a feed for raising pet crabs at a juvenile crab period and a production method of the feed. The feed comprises the following components in parts by weight: 40-60 parts of fish meal, 20-30 parts of soybean meal, 5-15 parts of meat and bone meal, 20-40 parts of desalinated whey powder, 1-5 parts of feed grade dicalcium phosphate, 1-4 parts of calcium lactate, 5-10 parts of bran, 1-5 parts of middling,1-5 parts of fish oil, 1-5 parts of edible oil, 0.1-1 part of EM compound bacteria, 0.5-1 part of a vitamin mixer, 1-5 parts of xanthophyll, 0.5-1 part of docosa-hexaenoic, 0.1-1 part of taurine, 0.1-1 part of L-carnitine and 1-10 parts of eicosatetraenoic acid. The feed does not stimulate intestinal tracts of juvenile crabs and is varied in nutrient components, the skeleton growing ability of the juvenile crabs is improved, and the immunity of the juvenile crabs is effectively improved.

The present invention relates to mutant Δ5 desaturases, which have the ability to convert dihomo-γ-linolenic acid [DGLA; 20:3 ω-6] to arachidonic acid [ARA; 20:4 ω-6] and / or eicosatetraenoic acid [ETA; 20:4 ω-3] to eicosapentaenoic acid [EPA; 20:5 ω-3] and which possess at least one mutation within the HPGG motif of the cytochrome b5-like domain. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding Δ5 desaturases, along with a method of making long chain polyunsaturated fatty acids [“PUFAs”] using these mutant Δ5 desaturases in oleaginous yeast, are disclosed.

The invention discloses broken-wall spirulina milk powder. According to the formula, the broken-wall spirulina milk powder consists of the following raw materials in parts by weight: 400-600 parts of fresh milk, 20-40 parts (4.4-5.6%) of spirulina, 4-10 parts (0.9-1.4%) of concentrated whey protein powder, 1-6 parts of walnut oil, 1-6 parts of soy isolate protein, 1-6 parts of apricot kernel powder, 10-20 parts of fruit and vegetable cellulose powder, 2-8 parts of fructo-oligosaccharide, 2-8 parts of deep sea fish oil, 2-8 parts of a beta-linoleic growth repair factor, 0.2-0.6 part of docosahexaenoic acid, 0.4-0.8 part of eicosatetraenoic acid, 0.1-0.5 part of complex vitamin and 0.2-0.5 part of complex trace element. The broken-wall spirulina milk powder disclosed by the invention can be used for boosting the immunity of a mother, enhancing the health of the mother and benefiting healthy development of a fetus.

The invention relates to the field of formula milk powder, and discloses formula milk powder for promoting growth and development of children and a preparation method thereof. The formula milk powdercomprises the following components: raw milk, whey, bovine colostrum, galactooligosaccharide, fructo-oligosaccharide, isomaltooligosaccharide, stachyose, bifidobacterium animalis, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum, multivitamins, fruit and vegetable powder, docosahexaenoic acid, eicosatetraenoic acid, lutein and lactase. In the preparation method of the milk powder, the raw milk, the whey, the bovine colostrum and the multivitamins are mixed by a wet method to prepare dry powder, and then the dry powder is mixed with the remaining components by a dry method, and the preparation method combining the two methods ensures the integrity and effectiveness of various components in the milk powder. By adding a variety of probiotics, the formula milk powderconstructs diversified intestinal flora for infants and promotes the intestinal development of the infants, thereby promoting the digestion and absorption of nutrients and the growth and developmentof the children during the growth process.

The invention relates to a milk powder capable of improving the infant's immunity. The milk powder is composed of the following raw materials in parts by weight: 600 to 800 parts of high-oil desalted whey powder, 100 to 200 parts of whole milk powder, 3 to 5 parts of hydrolyzed whey protein powder, 1 to 3 parts of whey protein powder, 2 to 5 parts of galactooligosaccharide, 1 to 3 parts of fructo-oligosaccharide, 1 to 3 part of docosahexaenoic acid (DHA), 1 to 3 parts of eicosatetraenoic acid (ETA) 0.4 to 1 part of lactoferrin, 0.05 to 0.07 part of bifidobacterium, 3 to 6 parts of multi-vitamins, and 2 to 7 parts of composite mineral substances. The milk powder can provide enough nutrients for the growth of infants, can be easily absorbed by the infants, and is capable of improving the infant's immunity and reducing the phenomenon of excessive internal heat, diarrhea, or constipation caused by dyspepsia. The milk powder is produced through a dry-mixing technology, thus the loss of active substances (EHA, ETA, etc.) during the process of wet process addition is avoided, and the activity loss of lactoferrin and bifidobacterium in the wet process addition is maximally reduced.

Leukotriene B4, 5S,12R-dihydroxy-6,8,10,14(Z,E,E,Z)-eicosatetraenoic acid, is a twenty carbon tetra-unsaturated fatty acid. No crystal forms of leukotriene B4 (LTB4) are known in the art. The present inventors have discovered a crystal form of LTB4 and the present invention therefore relates to crystal forms of LTB4 in general, and the novel crystal form A of LTB4 in particular.

The invention discloses formula milk powder for infant of one to three years old. The raw materials of the milk powder per ton comprise: 585 to 610 kg of base powder, 176 to 198 kg of demineralized whey powder, 128 to 145 kg of dried skim milk, 22 to 27 kg of whole milk powder, 18.5 to 21 kg of concentrated whey protein powder, 14.5 to 18 kg of hydrolyzed whey protein powder, 1.8 to 2.5 kg of eicosatetraenoic acid, 1.5 to 2.0 kg of docosahexaenoic acid, and 7.7 to 12.5 kg of compound nutrition enhancer. The base powder is mixed with added components to facilitate control over on the basic components of the milk powder, and the basic components can be elastically adjusted as required subsequently. A protein structure can be modified by using the hydrolyzed whey protein powder, so that the quantity of antigen active substances is greatly reduced, and the outbreak of infant's atopic dermatitis is reduced.

The invention discloses a novel serum lipid metabolite composition and application of the serum lipid metabolite composition as a marker in preparation of a non-smoking female lung cancer diagnostic kit. The serum lipid metabolite composition comprises eicosadienoic acid FA C20:2, eicosatetraenoic acid FA C20:4, tetracosatetraenoic acid FA C24:4, phosphatidylcholine PC 20:1 / 22:6, phosphatidylinositol PI18:0 / 20:5 and phosphatidyl ethanolamine PE18:0p / 22:4. The serum lipid metabolite composition can be used for auxiliary diagnosis of non-smoking female lung cancer, and has the characteristics of low detection cost, good repeatability, and high sensitivity and specificity. Meanwhile, the lipid metabolite composition also has a good effect on diagnosis of early-stage lung cancer of non-smoking females.

The invention discloses a method for extracting unsaturated fatty acid from an Asia grateloupia filicina. The method comprises the following steps: washing Asia grateloupia filicina clean; adding a composite cellulase according to the mass ratio of 1:100 and acting at the temperature of 50 DEG C for 2h; draining, drying and smashing to obtain the grateloupia filicina powder; adding the grateloupia filicina powder into petroleum ether, soaking for 24h, performing water bath backflow, filtering and centrifuging to obtain supernate; adding a saponified solution to the supernate, adding a hydrochloric acid solution by the end of saponification, and adjusting the PH value to 3.4-4 to obtain the unsaturated fatty acid. The gas chromatography shows that in the unsaturated fatty acid extracted from the grateloupia filicina pretreated by the composite cellulase, the content of timnodonic acid (C20:5) and eicosatetraenoic acid (C20:4) is greater than 75% of the total unsaturated fatty acid and is about 50% higher than that of the direct extraction process. A method for efficiently extracting the unsaturated fatty acid from the Asia grateloupia filicina is established for the first time and a scientific basis for the efficient comprehensive utilization of Asia grateloupia filicina is provided.

The present invention relates to milk powder for promoting absorption of infants and young children and a preparation method thereof. The product comprises 400-600 parts of fresh milk, 20-40 parts ofdesalted whey powder, 4-10 parts of concentrated whey protein powder, 4-10 parts of n-3 polyunsaturated fatty acids, 10-15 parts of n-6 polyunsaturated fatty acids, 1-6 parts of walnut oil, 1-5 partsof lutein crystals, 4-10 parts of biological growth factors, 6x10<6>-15x10<6> of active bifidobacterium longum, 4-10 parts of bifidobacterium multiplication factors, 2-8 parts of fructo-oligosaccharides, 0.2-0.6 part of docosahexaenoic acid, 0.4-0.8 part of eicosatetraenoic acid, 1-5 parts of compound fruit and vegetable powder, 0.06-0.1 part of choline, 0.03-0.05 part of taurine, 0.1-0.5 part ofmultivitamin and 0.2-0.5 part of compound trace elements. Due to the presence of the active bifidobacterium longum, the active bifidobacterium longum can effectively improve intestinal flora distribution of the infants, promote absorption of nutrients by the infants and young children, and improve immunity of the infants and young children.